Jong‐Mu Sun

12.1k total citations
234 papers, 7.1k citations indexed

About

Jong‐Mu Sun is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Jong‐Mu Sun has authored 234 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 169 papers in Pulmonary and Respiratory Medicine, 156 papers in Oncology and 49 papers in Surgery. Recurrent topics in Jong‐Mu Sun's work include Lung Cancer Treatments and Mutations (134 papers), Lung Cancer Research Studies (58 papers) and Cancer Immunotherapy and Biomarkers (44 papers). Jong‐Mu Sun is often cited by papers focused on Lung Cancer Treatments and Mutations (134 papers), Lung Cancer Research Studies (58 papers) and Cancer Immunotherapy and Biomarkers (44 papers). Jong‐Mu Sun collaborates with scholars based in South Korea, United States and China. Jong‐Mu Sun's co-authors include Myung‐Ju Ahn, Keunchil Park, Jin Seok Ahn, Se‐Hoon Lee, Yoon‐La Choi, Bo Mi Ku, Hyun Ae Jung, Joungho Han, Sung Hee Lim and Myung‐Ju Ahn and has published in prestigious journals such as Nucleic Acids Research, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Jong‐Mu Sun

229 papers receiving 7.0k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Jong‐Mu Sun	4.8k	4.4k	1.5k	1.2k	1.0k	234	7.1k
Ranee Mehra	4.1k 0.9×	2.3k 0.5×	1.5k 1.0×	1.4k 1.1×	746 0.7×	194	6.5k
Sandrine Marréaud	3.8k 0.8×	4.8k 1.1×	1.6k 1.1×	2.7k 2.2×	633 0.6×	145	7.7k
Jamie E. Chaft	7.0k 1.5×	6.4k 1.5×	1.9k 1.3×	855 0.7×	1.5k 1.5×	175	10.2k
Todd W. Bauer	4.1k 0.9×	3.0k 0.7×	1.4k 1.0×	3.7k 3.1×	1.1k 1.1×	185	7.1k
Lori J. Wirth	4.3k 0.9×	2.4k 0.5×	2.0k 1.3×	1.8k 1.5×	961 0.9×	260	9.9k
Catherine Delbaldo	6.3k 1.3×	2.7k 0.6×	1.8k 1.2×	1.6k 1.3×	2.2k 2.1×	48	8.3k
Steven J. Cohen	5.0k 1.0×	1.8k 0.4×	1.2k 0.8×	1.2k 1.0×	2.1k 2.0×	174	6.6k
Thomas E. Stinchcombe	3.9k 0.8×	3.7k 0.9×	1.7k 1.2×	664 0.6×	824 0.8×	215	6.9k
Bartomeu Massutí	4.6k 1.0×	3.6k 0.8×	1.5k 1.0×	967 0.8×	1.1k 1.1×	199	6.5k
Min‐Hee Ryu	3.7k 0.8×	4.5k 1.0×	847 0.6×	2.4k 2.0×	455 0.4×	327	7.6k

Countries citing papers authored by Jong‐Mu Sun

Since Specialization

Citations

This map shows the geographic impact of Jong‐Mu Sun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jong‐Mu Sun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jong‐Mu Sun more than expected).

Fields of papers citing papers by Jong‐Mu Sun

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jong‐Mu Sun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jong‐Mu Sun. The network helps show where Jong‐Mu Sun may publish in the future.

Co-authorship network of co-authors of Jong‐Mu Sun

This figure shows the co-authorship network connecting the top 25 collaborators of Jong‐Mu Sun. A scholar is included among the top collaborators of Jong‐Mu Sun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jong‐Mu Sun. Jong‐Mu Sun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hwang, Soohyun, Boram Lee, Hye Min Kim, et al.. (2025). Artificial intelligence-powered spatial analysis of tumor microenvironment in patients with non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitor. Journal for ImmunoTherapy of Cancer. 13(10). e012374–e012374. 1 indexed citations

Kim, Young Saing, Keon Uk Park, Jang Ho Cho, et al.. (2024). Clinical Outcomes of Maintenance Durvalumab After Definitive Concurrent Chemoradiotherapy in Unresectable Locally Advanced Stage III NSCLC According to EGFR and ALK Status: Korean Cancer Study Group LU-22-18. JTO Clinical and Research Reports. 5(12). 100734–100734. 1 indexed citations

Sun, Jong‐Mu, Antoine Adenis, Peter C. Enzinger, et al.. (2024). LEAP-014: first-line lenvatinib + pembrolizumab + chemotherapy in advanced/metastatic esophageal squamous cell carcinoma. Future Oncology. 20(35). 2709–2721. 2 indexed citations

Okamoto, Isamu, Shoichi Kuyama, Nicolas Girard, et al.. (2024). TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer. Future Oncology. 20(37). 2927–2936. 6 indexed citations

Park, Sehhoon, Tae Hee Hong, Soohyun Hwang, et al.. (2024). Comprehensive analysis of transcription factor-based molecular subtypes and their correlation to clinical outcomes in small-cell lung cancer. EBioMedicine. 102. 105062–105062. 22 indexed citations

Kim, Young-Gon, Boram Lee, Hyun Ae Jung, et al.. (2024). Clinical utility of circulating tumor DNA profiling in detecting targetable fusions in non-small cell lung cancer. Frontiers in Oncology. 14. 1463341–1463341.

Hong, Joo-Hyun, Jiyun Lee, Sehhoon Park, et al.. (2024). Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune‐related hepatitis in non–small cell lung cancer patients with chronic hepatitis B. Cancer. 130(9). 1693–1701. 3 indexed citations

Park, Sehhoon, Yu Jung Kim, Young Joo Min, et al.. (2023). Biomarker‐driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer. Cancer. 130(4). 541–552. 15 indexed citations

Ku, Bo Mi, Sehhoon Park, Hyun Ae Jung, et al.. (2022). Evaluation of MET alteration in EGFR-mutant non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor from paired biopsy: A retrospective cohort study. SHILAP Revista de lepidopterología. 6(4). 233–242. 1 indexed citations

10.

Yang, Kyungmi, Dongryul Oh, Jae Myoung Noh, et al.. (2021). Feasibility of an Interactive Health Coaching Mobile App to Prevent Malnutrition and Muscle Loss in Esophageal Cancer Patients Receiving Neoadjuvant Concurrent Chemoradiotherapy: Prospective Pilot Study. Journal of Medical Internet Research. 23(8). e28695–e28695. 21 indexed citations

11.

Lee, Min Ho, Kyung Rae Cho, Jung Won Choi, et al.. (2020). Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis : The Role of Gamma Knife Radiosurgery. Journal of Korean Neurosurgical Society. 64(2). 271–281. 11 indexed citations

12.

Park, Seo‐Young, S.T. Kim, Jin Hyoung Kang, et al.. (2020). A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy. Annals of Oncology. 31(10). 1397–1404. 122 indexed citations

13.

Hong, Tae Hee, Hongui Cha, Joonho Shim, et al.. (2020). Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity. Journal for ImmunoTherapy of Cancer. 8(2). e001199–e001199. 10 indexed citations

14.

Kim, Kyung Hwan, Jinhyun Cho, Bo Mi Ku, et al.. (2019). The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors. Clinical Cancer Research. 25(7). 2144–2154. 132 indexed citations

15.

Park, Sehhoon, Hayoon Lee, Boram Lee, et al.. (2019). DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC. Journal of Thoracic Oncology. 14(9). 1640–1650. 58 indexed citations

16.

Byeon, Seonggyu, Boram Lee, Woong‐Yang Park, et al.. (2019). Benefit of Targeted DNA Sequencing in Advanced Non–Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests. Clinical Lung Cancer. 21(3). e182–e190. 7 indexed citations

17.

Lee, Kang-Kook, Hyun Ae Jung, Jong‐Mu Sun, et al.. (2019). Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea. Cancer Research and Treatment. 52(1). 292–300. 19 indexed citations

18.

Lee, Ji Yun, Jong‐Mu Sun, Sung Hee Lim, et al.. (2015). A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non–Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib. Clinical Cancer Research. 22(9). 2139–2145. 28 indexed citations

19.

Lim, Sung Hee, Jin Yong Lee, H.S. Kim, et al.. (2014). A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer. Annals of Oncology. 26(4). 762–768. 70 indexed citations

20.

Sun, Jong‐Mu, et al.. (2008). Efficacy and Toxicity of Pemetrexed as a Third-line Treatment for Non-small Cell Lung Cancer. Japanese Journal of Clinical Oncology. 39(1). 27–32. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact